Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials

JR Ussher, AA Greenwell, MA Nguyen, EE Mulvihill - Diabetes, 2022 - Am Diabetes Assoc
As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of
debilitating cardiovascular complications. Given the significant association between …

New antidiabetic therapy and HFpEF: light at the end of tunnel?

M Tadic, C Sala, S Saeed, G Grassi, G Mancia… - Heart Failure …, 2021 - Springer
New antidiabetic therapy that includes sodium-glucose co-transporter 2 (SGLT2) inhibitors,
glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) …

The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF

C Withaar, LMG Meems, EE Nollet… - Basic to Translational …, 2023 - jacc.org
Obesity-related heart failure with preserved ejection fraction (HFpEF) has become a well-
recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may …

Quercetin ameliorates oxidative stress, inflammation and apoptosis in the heart of streptozotocin-nicotinamide-induced adult male diabetic rats

J Roslan, N Giribabu, K Karim, N Salleh - Biomedicine & Pharmacotherapy, 2017 - Elsevier
Introduction Quercetin is known to possess beneficial effects in ameliorating diabetic
complications, however the mechanisms underlying cardioprotective effect of this compound …

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

MB Bizino, IM Jazet, JJM Westenberg… - Cardiovascular …, 2019 - Springer
Background Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of
this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with …

A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis

C Burelle, V Clapatiuc, S Deschênes… - Communications …, 2024 - nature.com
Lean patients with NAFLD may develop cardiac complications independently of pre-existent
metabolic disruptions and comorbidities. To address the underlying mechanisms …

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE …

H Yamada, A Tanaka, K Kusunose, R Amano… - Cardiovascular …, 2017 - Springer
Background Diabetes is associated closely with an increased risk of cardiovascular events,
including diastolic dysfunction and heart failure that leads to a shortening of life expectancy …

Three‐dimensional global left ventricular myocardial strain reduced in all directions in subclinical diabetic cardiomyopathy: A systematic review and meta‐analysis

SM Ghoreyshi‐Hefzabad, P Jeyaprakash… - Journal of the …, 2021 - Am Heart Assoc
Background Three‐dimensional (3D) speckle tracking echocardiography can identify
subclinical diabetic cardiomyopathy without geometric assumption and loss of speckle from …

Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study

P Kumarathurai, A Sajadieh, C Anholm… - Cardiovascular …, 2021 - Springer
Background Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus
(T2DM) and is associated with overweight, glucose dysregulation and coronary artery …

Glucagon‐like peptide‐1 receptor agonist treatment of high carbohydrate intake‐induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction …

A Durak, E Akkus, AG Canpolat… - Clinical and …, 2022 - Wiley Online Library
The pleiotropic effects of glucagon‐like peptide‐1 receptor (GLP‐1R) agonists on the heart
have been recognised in obese or diabetic patients. However, little is known regarding the …